Filing Flows › UroGen Pharma (URGN) › Q3 2026 › vs Q3 2025
UroGen Pharma (URGN) Q3 2026 vs Q3 2025 (year over year)
UroGen Pharma's revenue rose $61.5M (+224%) from $27.5M in Q3 2025 to $89.0M in Q3 2026. The biggest changes: Zusduri +$66.3M (38×); Jelmyto −$4.7M (-18%).
UroGen Pharma, Q3 2026: revenue $89.0M (+224% year over year), operating margin 9.4%, net loss $1.5M, operating cash flow −$15.2M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Zusduri | $68.0M | $1.8M | $66.3M | 38× |
| Jelmyto | $21.0M | $25.7M | −$4.7M | -18% |
| Revenue | $89.0M | $27.5M | $61.5M | +224% |
| Net loss | $1.5M | $33.3M | −$31.9M | -96% |
| Costs & expenses | $90.5M | $61.9M | $28.6M | +46% |
| Operating costs | $80.7M | $54.9M | $25.8M | +47% |
| Interest & other, net | $8.8M | $7.0M | $1.8M | +25% |
| Income tax | $1.0M | −$1.1M | $2.1M | — |
| Cost of revenue | $7.5M | $3.3M | $4.2M | +129% |
| Research & development | $26.0M | $14.0M | $12.0M | +85% |
| SG&A | $47.2M | $37.6M | $9.6M | +26% |
| Operating cash sources | $21.5M | $45.4M | −$23.9M | -53% |
| Depreciation & amortization | $100K | $100K | $0 | 0% |
| Share-based compensation | $6.2M | $3.0M | $3.2M | +106% |
| Cash used in operations | $15.2M | $42.3M | −$27.1M | -64% |
| Net loss absorbed | $1.5M | $33.3M | −$31.9M | -96% |
| Working capital & other | $20.1M | $12.1M | $8.0M | +67% |
Questions
How much did UroGen Pharma's revenue grow year over year in Q3 2026?
UroGen Pharma's revenue rose $61.5M (+224%) from $27.5M in Q3 2025 to $89.0M in Q3 2026.
What drove UroGen Pharma's revenue change in Q3 2026?
Zusduri +$66.3M (38×); Jelmyto −$4.7M (-18%).